4-[[[1-(2-Fluorophenyl)cyclopentyl]amino]methyl]-2-[(4-methylpiperazin-1-yl)methyl]phenol

ID: ALA3590544

Chembl Id: CHEMBL3590544

Cas Number: 1287451-26-6

PubChem CID: 46965865

Max Phase: Preclinical

Molecular Formula: C24H32FN3O

Molecular Weight: 397.54

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  CN1CCN(Cc2cc(CNC3(c4ccccc4F)CCCC3)ccc2O)CC1

Standard InChI:  InChI=1S/C24H32FN3O/c1-27-12-14-28(15-13-27)18-20-16-19(8-9-23(20)29)17-26-24(10-4-5-11-24)21-6-2-3-7-22(21)25/h2-3,6-9,16,26,29H,4-5,10-15,17-18H2,1H3

Standard InChI Key:  RMYLFPZPIDTXQK-UHFFFAOYSA-N

Associated Targets(Human)

BT-474 (2113 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HMEC (560 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
NR1D2 Tchem Nuclear receptor subfamily 1 group D member 2 (13 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
NR1D1 Tchem Nuclear receptor subfamily 1 group D member 1 (332 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 397.54Molecular Weight (Monoisotopic): 397.2529AlogP: 3.84#Rotatable Bonds: 6
Polar Surface Area: 38.74Molecular Species: NEUTRALHBA: 4HBD: 2
#RO5 Violations: HBA (Lipinski): 4HBD (Lipinski): 2#RO5 Violations (Lipinski):
CX Acidic pKa: 8.96CX Basic pKa: 8.24CX LogP: 3.55CX LogD: 2.60
Aromatic Rings: 2Heavy Atoms: 29QED Weighted: 0.78Np Likeness Score: -0.95

References

1. Torrente E, Parodi C, Ercolani L, De Mei C, Ferrari A, Scarpelli R, Grimaldi B..  (2015)  Synthesis and in Vitro Anticancer Activity of the First Class of Dual Inhibitors of REV-ERBβ and Autophagy.,  58  (15): [PMID:26135471] [10.1021/acs.jmedchem.5b00511]
2. He S, Li Q, Jiang X, Lu X, Feng F, Qu W, Chen Y, Sun H..  (2018)  Design of Small Molecule Autophagy Modulators: A Promising Druggable Strategy.,  61  (11): [PMID:29211480] [10.1021/acs.jmedchem.7b01019]
3. Uriz-Huarte A,Date A,Ang H,Ali S,Brady HJM,Fuchter MJ.  (2020)  The transcriptional repressor REV-ERB as a novel target for disease.,  30  (17): [PMID:32738989] [10.1016/j.bmcl.2020.127395]
4. Ye W, Fan C, Fu K, Wang X, Lin J, Nian S, Liu C, Zhou W..  (2022)  The SAR and action mechanisms of autophagy inhibitors that eliminate drug resistance.,  244  [PMID:36283182] [10.1016/j.ejmech.2022.114846]

Source